Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding
Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding supports educators, patients, and caregivers through independent therapeutic education to address treatment gaps and barriers to equitable healthcare access.
Browse similar grants
Funder: Johnson & Johnson (Janssen)
Due Dates: Approximately November 1, 2026 (anticipated ITCI portal availability) | Six weeks before program start (general submission lead time)
Funding Amounts: No specific ITCI funding amount or award range published
Summary: Supports independent training and education in neuroscience, oncology, and immunology, including initiatives addressing barriers to equitable healthcare access.
Key Information: 2027 grant requests will not be accepted until ITCI is available in the J&J CyberGrants Portal.
Description
Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding, supported by Johnson & Johnson, supports independent training and education initiatives in neuroscience, oncology, and immunology. Priorities include therapeutic education and initiatives serving communities facing barriers to equitable healthcare access and representation. Requests are evaluated under internal and external guidelines and policies.
The program’s educational interests encompass disease awareness, treatment decisions, emerging clinical evidence, safety, relapse prevention, and coordination among healthcare professionals, patients, and caregivers. Neuroscience interests include schizophrenia, major depressive disorder, and treatment-resistant depression. Oncology interests span multiple myeloma, acute myeloid leukemia, and several solid tumors. Immunology interests include inflammatory bowel disease, psoriasis, inflammatory arthritis, and generalized myasthenia gravis, with emphasis on identifying suboptimally treated patients, interpreting guidelines, and supporting professional development.
